Amedisys — Q1 2022 Earnings Presentation
18 slides from Amedisys's earnings presentation, Apr 27, 2022
Slide 1: Amedisys First Quarter 2022 Earnings Call Supplemental Slides
Amedisys First Quarter 2022 Earnings Call Supplemental Slides April 28th, 2022 Exhibit 99.2
Slide 2: Forward-looking statements
This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could cau
Slide 3: Our Key Areas of Focus
Our Key Areas of Focus Strategic areas of focus and progress made during Q1’22 Home Health*: Total same store admissions +2% Hospice: Total same store admissions +2%, ADC -3% Personal Care: PC Network drove ~$345K in revenue to Home Health and Hospice via care coordination 1 Organic Growth Quality:
Slide 4: Highlights and Summary Financial Results (Adjusted): 1Q 2022
Highlights and Summary Financial Results (Adjusted): 1Q 2022(1) Home Health total same store admissions +2%; Hospice same store admissions +2%; EBITDA margin decline driven by the addition of Contessa, Hospice ADC decline and labor costs The financial results for the three-month periods ended March
Slide 5: Reimbursement models and care center footprint
Medicare FFS: Reimbursed over a 30-day period of care Private Episodic: MA and Commercial plans who reimburse us over a 30-day period of care, majority of which range from 95% - 100% of Medicare rates Per Visit: Managed care, Medicaid and private payors reimbursing us per visit performed Hospice Per
Slide 6: Home Health and Hospice Segment (Adjusted) – 1Q 2022
Home Health and Hospice Segment (Adjusted) – 1Q 2022(1) Revenue per Episode up 2.8% (primarily due to +3.2% rate increase effective 1/1/2022 partially offset by higher LUPAs and LBPs driven by Omicron and a shift in patient mix) Y/Y CPV up $9.09 (+9.4%, primarily due to planned wage increases, wage
Slide 7: General & Administrative Expenses – Adjusted
General & Administrative Expenses – Adjusted (1,2) Notes: Year over year total G&A as a percentage of revenue increased 110 basis points ($9 million); $2 million increase excluding Contessa (G&A as a % of revenue excluding Contessa = 31.8%) Increases due to the addition of resources to support growt
Slide 8: Operational Excellence: Home Health Cost Per Visit (CPV)-Adjusted
Operational Excellence: Home Health Cost Per Visit (CPV)-Adjusted YOY Total CPV impacted by planned wage increases, wage inflation (primarily sign-on bonuses) and an increase in new hire pay *Note: Direct comparison with industry competitors CPV calculation $87.67 $96.28 $95.64 Components 1Q’21 4Q’2
Slide 9: Driving Top Line Growth
Driving Top Line Growth Home Health total volume, Hospice admissions and ADC, as well as Personal Care billable hours lagging due to prolonged COVID-19 impacts (staffing challenges and increase in hospice discharge rate) Home Health Total Volume Hospice Growth Personal Care Total Hours / Quarter
Slide 10: Industry Leading Quality Scores
Industry Leading Quality Scores Amedisys maintains a 4-Star average in the Jul 2022 HHC Preview with 99% of our providers (representing 99% of care centers) at 4+ Stars and 76% of our providers (representing 81% of care centers) at 4.5+ Stars. 29 Amedisys providers (representing 43 care centers) rat
Slide 11: Hospice Quality: Moving Towards Best-in-Class
Hospice Quality: Amedisys Hospice Continues to Move Towards Best-in-Class Hospice Quality Notes: Included in the above analysis are active care centers. Acquired locations were only included if their acquisition date was before the start of the reporting window. Above excludes Asana, Aseracare, and
Slide 12: Debt and Liquidity Metrics
Debt and Liquidity Metrics Net leverage ~1.3x Net debt defined as total debt outstanding ($446.1M) less cash ($70.9M). Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($287.3M). Liquidity defined as the sum of cash balance and available revolving line of cre
Slide 13: Cash Flow Statement Highlights
Cash Flow Statement Highlights (1) COVID-19 relief payroll tax deferral of ~$55M (half paid in December 2021; remainder due in December 2022). Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments.
Slide 14: Income Statement Adjustments
Income Statement Adjustments (1) The financial results for the three-month periods ended March 31, 2021, June 30, 2021, September 30, 2021, December 31, 2021 and March 31, 2022 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP fi
Slide 15: 2022 Guidance
2022 Guidance
Slide 16: Amedisys 2022 Guidance
Amedisys 2022 Guidance Revenue, EBITDA and EPS guidance ranges for FY 2022 ($M except for EPS) AMED Core Performance High Acuity Care Total AMED Adjusted Revenue $2,274 - $2,309 $56 $2,330 - $2,365 Adjusted EBITDA $301 - $311 ($26) $275 - $285 Adjusted EPS $5.88 - $6.10 ($0.65) $5.23 - $5.45 Guidanc
Slide 17: Environmental, Social, Governance (E.S.G.) Considerations
Environmental, Social, Governance (E.S.G.) Considerations
Slide 18: Environmental, Social, Governance (E.S.G.) Considerations
Environmental, Social, Governance (E.S.G.) Considerations Sustainable, high-quality, patient focused, home-based care model Environmental, Social, Governance Environmental Amedisys is dedicated to the sustainability of our business and the communities in which we serve Environmental health has a str